Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
UCL
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
UCL Business Ltd has commercialized IP from UCL resulting in 60+ spin-out companies, multiple IPOs (e.g., Achilles Therapeutics), and major clinical advances. Spinouts have programs in diverse stages, including recent public listings and major exits (e.g., BioVex acquired for $1B by Amgen for its cancer vaccine approach).
- Therapeutic areas
- Infectious DiseasesHematologyCardiovascularOncologyNeurology
- Modalities
- Gene therapyCell therapySmall moleculeMonoclonal antibodymRNA-based drugsRecombinant proteinRadiopharmaceuticalPeptidesAntibody-drug conjugateProtein
- Industry
- Investors
02
Partnerships
GlaxoSmithKlineSynconaThe Francis Crick InstituteCancer Research UKBritish Business BankEuropean Investment FundImperial Innovations
Beyond the preview
Go deeper on UCL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UCL.